Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review
P Csermely, T Korcsmáros, HJM Kiss, G London… - Pharmacology & …, 2013 - Elsevier
Despite considerable progress in genome-and proteome-based high-throughput screening
methods and in rational drug design, the increase in approved drugs in the past decade did …
methods and in rational drug design, the increase in approved drugs in the past decade did …
Principles and methods of integrative genomic analyses in cancer
VN Kristensen, OC Lingjærde, HG Russnes… - Nature Reviews …, 2014 - nature.com
Combined analyses of molecular data, such as DNA copy-number alteration, mRNA and
protein expression, point to biological functions and molecular pathways being deregulated …
protein expression, point to biological functions and molecular pathways being deregulated …
Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) has heterogeneous clinical and biological behavior.
Whole-genome and-exome sequencing has contributed to the characterization of the …
Whole-genome and-exome sequencing has contributed to the characterization of the …
Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia
J Lu, E Cannizzaro, F Meier-Abt, S Scheinost… - Nature cancer, 2021 - nature.com
Chronic lymphocytic leukemia (CLL) has a complex pattern of driver mutations and much of
its clinical diversity remains unexplained. We devised a method for simultaneous subgroup …
its clinical diversity remains unexplained. We devised a method for simultaneous subgroup …
High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia
ROR1 is an oncoembryonic orphan receptor found on chronic lymphocytic leukemia (CLL) B
cells, but not on normal postpartum tissues. ROR1 is a receptor for Wnt5a that may complex …
cells, but not on normal postpartum tissues. ROR1 is a receptor for Wnt5a that may complex …
miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1
We examined the microRNAs (miRNAs) expressed in chronic lymphocytic leukemia (CLL)
and identified miR-150 as the most abundant, but with leukemia cell expression levels that …
and identified miR-150 as the most abundant, but with leukemia cell expression levels that …
Protein-protein interaction networks: probing disease mechanisms using model systems
U Kuzmanov, A Emili - Genome medicine, 2013 - Springer
Protein-protein interactions (PPIs) and multi-protein complexes perform central roles in the
cellular systems of all living organisms. In humans, disruptions of the normal patterns of PPIs …
cellular systems of all living organisms. In humans, disruptions of the normal patterns of PPIs …
In silico investigations identified Butyl Xanalterate to competently target CK2α (CSNK2A1) for therapy of chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is an incurable malignancy of B-cells. In this study,
bioinformatics analyses were conducted to identify possible pathogenic roles of CK2α …
bioinformatics analyses were conducted to identify possible pathogenic roles of CK2α …
The cancer cell map initiative: defining the hallmark networks of cancer
Progress in DNA sequencing has revealed the startling complexity of cancer genomes,
which typically carry thousands of somatic mutations. However, it remains unclear which are …
which typically carry thousands of somatic mutations. However, it remains unclear which are …
The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience
DL Van Dyke, L Werner, LZ Rassenti… - British journal of …, 2016 - Wiley Online Library
This study revisited the Dohner prognostic hierarchy in a cohort of 1585 well‐documented
patients with chronic lymphocytic leukaemia. The duration of both time to first treatment …
patients with chronic lymphocytic leukaemia. The duration of both time to first treatment …